Michael Merger

1.2k total citations
21 papers, 959 citations indexed

About

Michael Merger is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Epidemiology. According to data from OpenAlex, Michael Merger has authored 21 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Surgery and 5 papers in Epidemiology. Recurrent topics in Michael Merger's work include Ovarian cancer diagnosis and treatment (5 papers), Renal cell carcinoma treatment (4 papers) and Gastrointestinal motility and disorders (3 papers). Michael Merger is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Renal cell carcinoma treatment (4 papers) and Gastrointestinal motility and disorders (3 papers). Michael Merger collaborates with scholars based in Germany, France and Canada. Michael Merger's co-authors include H. Kilbinger, Alexander Gebauer, Jan M. Orenstein, Phillip D. Smith, Martin F. Graham, Marty T. Sellers, Toshihide Shimada, Don A. Sibley, Michael W. Russell and Meg Mosteller‐Barnum and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Gut.

In The Last Decade

Michael Merger

20 papers receiving 935 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Michael Merger 323 269 201 178 130 21 959
Selene Meza‐Perez 339 1.0× 228 0.8× 143 0.7× 209 1.2× 55 0.4× 28 839
A Hizuta 282 0.9× 483 1.8× 200 1.0× 466 2.6× 146 1.1× 62 1.1k
Jerome I. Rotter 261 0.8× 391 1.5× 275 1.4× 85 0.5× 443 3.4× 14 1.1k
Colette Charland 493 1.5× 288 1.1× 101 0.5× 185 1.0× 106 0.8× 21 1.1k
Pedram Azimzadeh 176 0.5× 271 1.0× 166 0.8× 188 1.1× 132 1.0× 94 994
Keith Lai 70 0.2× 219 0.8× 239 1.2× 209 1.2× 86 0.7× 49 894
A. Robins 216 0.7× 231 0.9× 58 0.3× 163 0.9× 114 0.9× 24 725
Kazuya Makiyama 199 0.6× 161 0.6× 329 1.6× 101 0.6× 255 2.0× 56 856
E Clerici 714 2.2× 133 0.5× 132 0.7× 165 0.9× 75 0.6× 67 1.2k

Countries citing papers authored by Michael Merger

Since Specialization
Citations

This map shows the geographic impact of Michael Merger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Merger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Merger more than expected).

Fields of papers citing papers by Michael Merger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Merger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Merger. The network helps show where Michael Merger may publish in the future.

Co-authorship network of co-authors of Michael Merger

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Merger. A scholar is included among the top collaborators of Michael Merger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Merger. Michael Merger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heitz, Florian, Philipp Harter, E. Åvall‐Lundqvist, et al.. (2018). Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecologic Oncology. 152(2). 235–242. 8 indexed citations
2.
3.
Droz, Jean‐Pierre, J. Medioni, Christine Chevreau, et al.. (2014). Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. Anti-Cancer Drugs. 25(9). 1081–1088. 12 indexed citations
4.
Kristensen, Gunnar B., Philipp Harter, Olivier Trédan, et al.. (2014). Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. Journal of Clinical Oncology. 32(15_suppl). 5556–5556. 5 indexed citations
5.
Wong, Han Hsi, Christine Parkinson, Jonathan A. Ledermann, et al.. (2012). Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. PubMed. 3. 7–10. 1 indexed citations
6.
7.
Ledermann, Jonathan A., Allan Hackshaw, Gordon C. Jayson, et al.. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology. 29(28). 3798–3804. 164 indexed citations
8.
Bouché, Olivier, Frédérique Maindrault‐Gœbel, Michel Ducreux, et al.. (2011). Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.. PubMed. 31(6). 2271–81. 36 indexed citations
9.
Klebl, Frank, et al.. (2008). Ungewöhnlicher Fall einer disseminierten Sarkoidose mit führender gastrointestinaler Symptomatik. DMW - Deutsche Medizinische Wochenschrift. 124(3). 39–44. 1 indexed citations
10.
Merger, Michael, et al.. (2008). Riesenkotsteine bei habitueller Obstipation. DMW - Deutsche Medizinische Wochenschrift. 124(42). 1235–1238.
11.
Hügl, S & Michael Merger. (2007). Prolactin stimulates proliferation of the glucose-dependent beta-cell line INS-1 via different IRS-proteins.. PubMed. 8(6). 739–52. 17 indexed citations
12.
Maier, M., et al.. (2006). Retroperitoneal gas gangrene after colonoscopic polypectomy without bowel perforation in an otherwise healthy individual: report of a case. Langenbeck s Archives of Surgery. 391(2). 157–160. 11 indexed citations
13.
Merger, Michael, et al.. (2005). A rare case of hypalbuminaemic oedema: Figure 1. Gut. 54(3). 320–320. 1 indexed citations
14.
Merger, Michael, Joanne L. Viney, Rajka Borojevic, et al.. (2002). Defining the roles of perforin, Fas/FasL, and tumour necrosis factor α in T cell induced mucosal damage in the mouse intestine. Gut. 51(2). 155–163. 87 indexed citations
15.
Gahr, Scott A., et al.. (2002). Hepatocyte growth factor stimulates proliferation of pancreatic beta-cells particularly in the presence of subphysiological glucose concentrations. Journal of Molecular Endocrinology. 28(2). 99–110. 46 indexed citations
16.
Smith, Phillip D., Lesley E. Smythies, Meg Mosteller‐Barnum, et al.. (2001). Intestinal Macrophages Lack CD14 and CD89 and Consequently Are Down-Regulated for LPS- and IgA-Mediated Activities. The Journal of Immunology. 167(5). 2651–2656. 254 indexed citations
17.
McKay, Derek M., et al.. (1999). Characterization of enteric functional changes evoked by in vivo anti-CD3 T cell activation. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 276(3). R715–R723. 28 indexed citations
18.
Merger, Michael & Ken Croitoru. (1998). Infections in the immunopathogenesis of chronic inflammatory bowel disease. Seminars in Immunology. 10(1). 69–78. 14 indexed citations
19.
Smith, Phillip D., Edward N. Janoff, Michael Merger, et al.. (1997). Isolation and purification of CD14-negative mucosal macrophages from normal human small intestine. Journal of Immunological Methods. 202(1). 1–11. 83 indexed citations
20.
Gebauer, Alexander, Michael Merger, & H. Kilbinger. (1993). Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn-Schmiedeberg s Archives of Pharmacology. 347(2). 137–40. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Selene Meza‐Perez Breakdown of academic impact, for papers by A Hizuta Breakdown of academic impact, for papers by Jerome I. Rotter Breakdown of academic impact, for papers by Colette Charland Breakdown of academic impact, for papers by Pedram Azimzadeh Breakdown of academic impact, for papers by Keith Lai Breakdown of academic impact, for papers by A. Robins Breakdown of academic impact, for papers by Kazuya Makiyama Breakdown of academic impact, for papers by E Clerici
Rankless by CCL
2026